COSTA MESA, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today previewed its 24-week data from the Infergen® (Consensus Interferon) DIRECT trial through an abstract submitted to and accepted by the American Association for the Study of Liver Diseases (AASLD). Additional data, including 48 week data, will be presented as a late-breaker poster at the upcoming AASLD meeting in Boston on October 30, 2006.
